Ryvu Market Share Analysis for April 2026

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology.

Health > Biotechnology and Pharmaceuticals

Domainryvu.com

Year Founded2007

Employees51 - 200

Annual Revenue$15M - $25M

Ryvu

Ryvu (including company regionals)

ryvu.com

See more website traffic and engagement information

Ryvu Revenue up to April 2026 is 15M - 25M

revenue generated by Ryvu top domains

Ryvu top domains revenue over 3 years

Revenue for Ryvu top domains

ryvu.com15M - 25M

See more with Sales Intelligence

Total visits to Ryvu's top domains

Understand Ryvu market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ryvu.com5.7K

See more with Sales Intelligence

Avg. visit duration in Ryvu's top domains

Analyze Ryvu engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ryvu.com00:01:29

See more with Sales Intelligence

Avg. pageviews on Ryvu's top domains

See how Ryvu keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ryvu.com4.72

See more with Sales Intelligence

Ryvu top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Ryvu

These are the website technologies, by industry, used by Ryvu top domains

Widget (4)

Twemoji

Advertising (3)

Google Adsense

Payment & Currencies (3)

Euro

Conversion & Analytics (2)

Google Analytics

More Technologies

9

See all

News & Signals from Ryvu

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRyvu Therapeutics S.A attends event EHA 2026 congress.Quercus TFI S.A., a Polish asset manager, gains attention amid portfolio company Ryvu Therapeutics' disclosure of romacyklib clinical data presentation at EHA 2026 congress, per recent regulatory filing.

NewsRyvu Therapeutics S.A partners with BioNTech US Inc..Poland's clinical-stage drug cancer focused developer Ryvu Therapeutics (WSE: RVU) is entering a strategic agreement with Germany's BioNTech (Nasdaq: BNTX) to benefit Polish cancer patients by supporting trial site activation and patient recruitment for multiple investigational immunotherapies of BioNTech's oncology pipeline in Poland.

NewsRyvu Therapeutics S.A attends event European Hematology Association Congress 2025.Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the European Hematology Association Congress 2025 in June.